Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TNXP | 8-K | bullish | 5/10 | Tonix Pharmaceuticals disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M, up 27-36% sequentially from Q2's $1 | Oct 15, 2026 |
| ANL | 6-K | bullish | 5/10 | Adlai Nortye announced clinical trial collaboration and supply agreements with Lilly and Merck KGaA, Darmstadt, Germany | Oct 15, 2026 |
| LGND | PRESS-RELEASE | neutral | 1/10 | Ligand Pharmaceuticals announced it will report its Q3 2026 results on October 29, 2026. | Oct 15, 2026 |
| ADMA | PRESS-RELEASE | neutral | 4/10 | ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine detailing data from its opt | Oct 15, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in Waldenst | Oct 15, 2026 |
| ANL | PRESS-RELEASE | neutral | 4/10 | Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA for cetuximab, t | Oct 15, 2026 |
| AQST | PRESS-RELEASE | bullish | 7/10 | Aquestive Therapeutics announced FDA acceptance of its resubmitted NDA for Anaphylm (dibutepinephrine) sublingual film a | Oct 15, 2026 |
| IMCR | PRESS-RELEASE | neutral | 4/10 | Immunocore dosed the first patient in a Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate for | Oct 15, 2026 |
| IDXG | 8-K | bullish | 5/10 | Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M-$10.4M, representing ~15-18% YoY growth and ~11-14 | Oct 15, 2026 |
| CUVL | 6-K | neutral | 2/10 | Clinuvel Pharmaceuticals filed a Form 6-K with the SEC on October 15, 2026, furnishing an Appendix 3H notification of ce | Oct 15, 2026 |
| ZYME | PRESS-RELEASE | neutral | 1/10 | Zymeworks Inc. announced it will report its Q3 2026 results on November 9, 2026. | Oct 15, 2026 |
| IAM | EFFECT | bullish | 7/10 | Iambic Therapeutics' IPO registration (S-1, File No. 333-299057) was declared effective by the SEC on October 14, 2026. | Oct 15, 2026 |
| CUE | CLUSTER | bearish | 4/10 | CEO Lin Shao-Lee and VP Meluzio Michael Vincent sold a combined $307K in open-market sales on October 12, 2026. The CEO' | Oct 14, 2026 |
| OCGN | 8-K | mixed | 5/10 | Ocugen entered into an exclusive license agreement with Roots Pharmaceutical for OCU400, a modifier gene therapy for ret | Oct 14, 2026 |
| RADX | SC 13G | neutral | 3/10 | Regal Partners Funds Management Pty Ltd disclosed a passive 3.34% beneficial ownership stake in Radiopharm Theranostics | Oct 14, 2026 |
| ALMR | 144 | bearish | 5/10 | Qiming Venture Partners VIII-HC, L.P., a venture capital affiliate of Alamar Biosciences, has filed a Form 144 notice to | Oct 14, 2026 |
| ALMR | 144 | bearish | 6/10 | Qiming Venture Partners VI, L.P., a major venture backer of Alamar Biosciences, filed a Form 144 notice of intent to sel | Oct 14, 2026 |
| ALMR | 144 | neutral | 2/10 | Qiming Managing Directors Fund VI, L.P., a pre-IPO venture investor in Alamar Biosciences, filed a Form 144 on October 1 | Oct 14, 2026 |
| ABT | COURT-RULING | bullish | 5/10 | The court denied with prejudice the plaintiff's renewed motion for class certification in a putative class action allegi | Oct 14, 2026 |
| AZN | COURT-RULING | bullish | 4/10 | The Delaware Court of Chancery entered judgment in favor of Alexion (now AstraZeneca) on the remaining Milestone 1 CRE c | Oct 14, 2026 |
| NVS | COURT-RULING | neutral | 2/10 | The District of New Jersey granted plaintiff Andrew Isaacs' motion to remand his employment severance dispute against No | Oct 14, 2026 |
| HALO | PTAB-TRIAL | bearish | 7/10 | In a Final Written Decision, the PTAB held all challenged claims (1, 2, 6–15, 17–30) of Halozyme's U.S. Patent 12,060,59 | Oct 14, 2026 |
| MRK | PTAB-TRIAL | bullish | 5/10 | In a Final Written Decision in PGR2025-00024, the PTAB held all challenged claims (1, 2, 6–15, and 17–30) of Halozyme's | Oct 14, 2026 |
| MRK | PTAB-TRIAL | bullish | 6/10 | The PTAB issued a Final Written Decision in PGR2025-00030, holding all challenged claims (1, 2, and 6–30) of Halozyme's | Oct 14, 2026 |
| HALO | PTAB-TRIAL | bearish | 7/10 | The PTAB issued a Final Written Decision in PGR2025-00030, finding all challenged claims (1, 2, and 6–30) of Halozyme's | Oct 14, 2026 |
| INBX | INSIDER-BUY | bullish | 4/10 | CEO Mark Lappe purchased $426K of INBX stock in three open-market transactions on October 14, 2026, at an average price | Oct 14, 2026 |
| IAM | 3 | neutral | 2/10 | Kurt von Emster filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating he has become a Sec | Oct 14, 2026 |
| IAM | 3 | neutral | 1/10 | Mary Tagliaferri filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, disclosing 66,556 stock optio | Oct 14, 2026 |
| IAM | 3 | neutral | 2/10 | Shalini Sharp filed a Form 3 initial statement of beneficial ownership, reporting 66,556 stock options (right to buy) in | Oct 14, 2026 |
| IAM | 3 | neutral | 2/10 | William Rastetter, Chairperson of the Board of Iambic Therapeutics, filed a Form 3 initial statement of beneficial owner | Oct 14, 2026 |